Calvan® 100 mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
8Huntington disease1

8. Huntington disease


Clinical trials : 229 Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000203-16-ES
(EUCTR)
18/06/201821/05/2018Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. Chorea movements associated with Huntington's Disease
MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Calvan® 100 mg
INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE
SOM BiotechNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noSpain